ODM-104

DRUG3 trials

Sponsors

Orion Corporation, Orion Pharma

Conditions

CNS DiseaseHealthyHealthy Volunteers

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers

CompletedNCT01840423

Orion Corporation, Orion PharmaHealthy

Start: 2013-05-31End: 2014-12-31Updated: 2015-04-01

Dose-finding Pharmacokinetic Study in Healthy Males

CompletedNCT03055936

Orion Corporation, Orion PharmaHealthy Volunteers

Start: 2017-02-21End: 2017-06-09Updated: 2021-05-27

Blood-Brain Barrier Penetration of Therapeutic Agents in Human

CompletedNCT04571996

Orion Corporation, Orion PharmaCNS Disease

Start: 2020-10-29End: 2021-02-23Updated: 2021-04-13